The stock of Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) registered a decrease of 38.82% in short interest. CYCC?s total short interest was 155,100 shares in December as published by FINRA. Its down 38.82% from 253,500 shares, reported previously. With 121,000 shares average volume, it will take short sellers 1 days to cover their CYCC?s short positions. The short interest to Cyclacel Pharmaceuticals
: endlich etwas Erholung Ziel 2 $ - hoffentlich
Cyclacel Pharmaceuticals, Inc. (CYCC) of the Healthcare sector has changed by 5.73% and at noon is trading with a volume of 161,691 shares with a volatility this week of 9.65%. Cyclacel Pharmaceuticals, Inc. (CYCC) currently stands at $0.55, with a weekly performance of 1.980% and a 52 week low of 14.56%. Cyclacel Pharmaceuticals, Inc. (CYCC)?s monthly performance stands at ? 8.750% and Cyclacel Pharmaceuticals, Inc. (CYCC) is considered a stock to watch with an analyst rating of 2.00
Cyclacel Pharmaceuticals of Berkeley Heights provided highlights of a review of 2015 achievements and an outline of the company's key business objectives during a presentation at the Biotech Showcase 2016 Conference at the Parc 55 Wyndham Hotel in San Francisco. Accomplishments included a Phase 3 clinical trial evaluating sapacitabine in the treatment setting of elderly patients with acute myeloid leukemia, as well as patients with breast cancer. Results are expected to be reported by July. Cyclacel also advanced CYC065, a CDK2/9 inhibitor, into a Phase 1, first-in-human study that is beginning to determine the rationale for development of the drug in solid tumors and blood diseases.
Corporate developments include raising $10 million from a public offering of common stock, a sales agent agreement with Cantor Fitzgerald for up to another $8.3 million in stock, a license and supply agreement with ManRos Therapeutics regarding the development of oral seliciclib for the treatment of cystic fibrosis. Upcoming plans include a Paediatric Investigation Plan for sapacitabine with the European Medicines Agency. Info: www.cyclacel.com
Cyclacel's continued listing on NASDAQ is conditioned upon the Company demonstrating compliance with the minimum bid price requirement, as set forth in Listing Rule 5550(a)(2), by June 14, 2016, and also remaining in compliance on that date with NASDAQ's other continued listing requirements. Specifically, the Company must evidence a closing bid price for its common stock of at least $1.00 per share for a minimum of 10 consecutive business days by the close of business on June 14, 2016. The Panel's favorable determination follows a hearing that took place on March 31, 2016.